10-Q: STRATA Skin Sciences Q3 2025: Revenue Declines, Liquidity Secured

STRATA Skin Sciences reported a net loss of $1.6 million in Q3 2025 on reduced revenues, but secured its liquidity for the next 12 months by pausing debt covenants and raising capital.

Summary

• Net revenues decreased by 21.2% to $6.9 million for the three months ended September 30, 2025, compared to $8.8 million in the prior year period.
• For the nine months ended September 30, 2025, net revenues were $21.4 million, a 10.7% decrease from $24.0 million in the same period of 2024.
• The company reported a net loss of $1.6 million ($0.36 per share) for Q3 2025, an improvement from a net loss of $2.1 million ($0.51 per share) in Q3 2024.
• For the nine months ended September 30, 2025, the net loss was $6.3 million ($1.48 per share), compared to a net loss of $5.5 million ($1.50 per share) in the same period of 2024.
• Dermatology Recurring Procedures revenue slightly increased to $5.5 million in Q3 2025 from $5.4 million in Q3 2024, but decreased slightly for the nine-month period to $15.4 million from $15.4 million.
• Dermatology Procedures Equipment revenue significantly decreased to $1.4 million in Q3 2025 from $3.4 million in Q3 2024, and to $6.0 million for the nine-month period from $8.6 million.
• Gross profit percentage increased to 60.4% in Q3 2025 from 60.1% in Q3 2024, and to 57.3% for the nine-month period from 56.1% in 2024.
• As of September 30, 2025, there were 838 XTRAC systems placed in dermatologists' offices in the United States, a decrease from 864 at December 31, 2024.
• TheraClear devices placed in the United States increased to 161 as of September 30, 2025, from 135 as of September 30, 2024.
• A settlement gain of $0.7 million was recognized in Q3 2025 from resolving outstanding obligations with a supplier.
• The company identified an error in its sales tax liability accrual methodology, leading to a revision of previously issued financial statements and an additional goodwill impairment charge for 2023 and 2024.
• Working capital was negative $0.8 million as of September 30, 2025, compared to positive $3.2 million as of December 31, 2024.
• Net cash used in operating activities increased to $2.6 million for the nine months ended September 30, 2025, from $0.5 million in the prior year period.
• The company entered into Amendment No. 6 to its credit agreement in November 2025, pausing the minimum net revenue covenant compliance measurement through September 30, 2026.
• A Settlement and Mutual Release Agreement with Theravant in October 2025 released the company from $1.2 million in contingent consideration obligations, with a related $0.7 million intangible asset expected to be written off in Q4 2025.
• Raised $2.2 million in net proceeds from common stock sales in September 2025 and an additional $1.4 million in October 2025 through an at-the-market offering.
• Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, due to a material weakness in internal control over financial reporting related to a lack of detailed management review and technical accounting expertise.

Sentiment

Score: 3

Explanation: While the company has taken steps to address liquidity and going concern issues through debt covenant waivers and capital raises, and the Theravant settlement is positive, the significant revenue decline, increased net loss for the nine-month period, negative working capital, and identified material weakness in internal controls indicate ongoing operational and financial challenges. The capital raise helps liquidity but also suggests a continued reliance on external funding.

Positives

• Net loss decreased to $1.6 million in Q3 2025 from $2.1 million in Q3 2024.
• Gross profit percentage increased to 60.4% in Q3 2025 and 57.3% for the nine months ended September 30, 2025, indicating improved margin efficiency.
• Recognized a $0.7 million settlement gain in Q3 2025 from resolving a supplier dispute.
• The company's lender (MidCap) paused the minimum net revenue covenant for quarterly periods through September 30, 2026, providing financial flexibility.
• Management believes current cash and anticipated revenues are sufficient for liquidity for at least the next 12 months, alleviating substantial doubt about the company's ability to continue as a going concern.
• TheraClear device placements in the U.S. increased to 161 as of September 30, 2025, from 135 in the prior year.
• The settlement with Theravant eliminated $1.2 million in contingent consideration liability, reducing future obligations.
• Successfully raised $3.6 million in net proceeds from common stock sales in September and October 2025, bolstering cash reserves.

Negatives

• Total revenues decreased by 21.2% in Q3 2025 and 10.7% for the nine months ended September 30, 2025, compared to prior year periods.
• Net loss for the nine months ended September 30, 2025, increased to $6.3 million from $5.5 million in the prior year period.
• Dermatology Procedures Equipment revenue saw a significant decline of 59.6% in Q3 2025 and 29.9% for the nine months ended September 30, 2025.
• Working capital turned negative to $0.8 million as of September 30, 2025, from positive $3.2 million at December 31, 2024.
• Net cash used in operating activities increased substantially to $2.6 million for the nine months ended September 30, 2025, from $0.5 million in the prior year.
• The number of XTRAC systems placed in U.S. dermatologists' offices decreased to 838 from 864 since December 31, 2024.
• A material weakness in internal control over financial reporting was identified due to a lack of detailed management review and technical accounting expertise.
• An adverse New York sales tax ruling resulted in the execution of a $1.3 million appellate bond, and the company faces remaining accruals and ongoing appeals for sales tax assessments totaling $4.0 million in New York and California.
• An error in sales tax accrual methodology led to a cumulative overstatement of accrued expenses and an understatement of goodwill impairment in prior periods, requiring financial statement revisions.

Risks

• The ongoing COVID-19 pandemic and its variants continue to negatively impact business conditions, supply chains, workforce participation, and financial markets.
• The Russia-Ukraine War has disrupted the supply of noble gases (neon, krypton, xenon) essential for the company's lasers, impacting supply and increasing prices, with no assurance of uninterrupted supply.
• The Middle East conflict poses a risk to the company's distributors' businesses in the region, with unpredictable potential for a larger war.
• U.S. trade policy actions and increased import tariffs could adversely affect revenues, costs, or gross profit, and diminish customer demand.
• Uncertainty surrounding international trade policy and regulations, as well as protectionist measures, could negatively impact consumer confidence and spending.
• The company has historically experienced recurring losses and negative working capital, and its ability to continue as a going concern depends on raising capital.
• If current liquidity sources are insufficient, the company may need to sell additional debt or equity securities, which could dilute stockholders or involve restrictive covenants, and there is no assurance such financing will be available on favorable terms.
• There is a risk of allocating significant capital towards products or technologies for which market demand is lower than expected, potentially leading to abandoned efforts.
• The company may be subject to sales taxes in other states for previous years and in the future, plus potential interest and penalties, if its defenses against sales tax applicability do not prevail.

Future Outlook

Management believes that current cash and cash equivalents, combined with anticipated revenues and operating expense management, will be sufficient to satisfy liquidity requirements for at least the next 12 months, thereby alleviating substantial doubt about the company's ability to continue as a going concern. However, the company cannot predict short-term revenues and expenses due to potential future pandemics, ongoing geopolitical conflicts (Russia-Ukraine, Middle East), changes in U.S. trade policies, supply chain disruptions, and rising interest rates. If current sources are insufficient, the company may seek additional debt or equity financing, which could result in stockholder dilution or restrictive covenants, and there is no assurance such financing will be available on favorable terms.

Management Comments

• "Our strategy going forward is to continue to increase our direct-to-patient program for XTRAC advertising in the United States, targeting psoriasis and vitiligo patients through a variety of media and through our use of social media such as Facebook and X (formerly Twitter), and aimed at motivating them to seek out XTRAC treatments from our physician partners."
• "We monitor the results of our advertising expenditures in this area in order to effectively reach the more than 10 million patients in the United States we believe are afflicted with these diseases."
• "Based on our current business plan, we believe that our cash and cash equivalents, combined with the anticipated revenues from the sale or use of our products and operating expense management, will be sufficient to satisfy our working capital needs, capital asset purchases, outstanding commitments and other liquidity requirements associated with our existing operations for at least the next 12 months following the date of the issuance of these interim condensed consolidated financial statements, alleviating the factors that raised substantial doubt regarding the Company’s ability to continue as a going concern."

Industry Context

STRATA Skin Sciences operates in the medical technology sector, specifically focusing on dermatological conditions. The company faces industry-wide challenges such as global supply chain disruptions, particularly for noble gases critical to its laser systems, exacerbated by geopolitical conflicts like the Russia-Ukraine War. The impact of U.S. trade tariffs also presents a broader industry headwind affecting costs and demand. The company's strategy to increase direct-to-patient advertising for XTRAC highlights the competitive nature of the dermatology market and the importance of patient awareness and insurance reimbursement for treatment adoption. Expansion into acne care with TheraClear X positions the company in another significant dermatological segment, though it notes limited insurance reimbursement for such treatments.

Corporate Governance

Legal Proceedings

• Outstanding assessments from the states of New York and California aggregating to $5.0 million, including penalties and interest, related to sales and use tax audits covering periods from August 2017 through February 2025.
• The New York State Appellate Division ruled against the company in its sales tax appeal, affirming that the sale of XTRAC treatment codes is subject to sales tax. The company's motion to appeal to the New York State Court of Appeals was denied.
• New York executed on the $1.3 million appellate bond posted by the company. A remaining accrual of $0.7 million, including penalties and interest, is held for the Appellate Division ruling.
• The company is in the administrative process of appeal for remaining $1.9 million of assessments in New York and $2.4 million of assessments in California.
• The company is routinely a defendant in or party to pending and threatened legal actions and proceedings in the ordinary course of business, including employment and contract claims, and is subject to regulatory and governmental examinations.

Stakeholder Impact

• Shareholders: Experience dilution from recent and potential future equity offerings. Face impact from declining revenues, ongoing net losses, and the identified material weakness in internal controls. Benefit from the debt covenant waiver and Theravant settlement reducing future obligations.
• Employees: Workforce participation has been constrained by the COVID-19 pandemic, potentially affecting staffing and operations.
• Customers (Physician Practices): Some partner physician practices closed permanently due to the COVID-19 pandemic. Demand may be diminished by increased prices due to tariffs.
• Suppliers: Supply chains for critical components like noble gases are disrupted and prices impacted by geopolitical events, potentially affecting the company's ability to source materials.
• Creditors (MidCap Financial Trust): The debt covenant waiver provides temporary relief, but the underlying financial performance and negative working capital indicate ongoing credit risk. Security interests in substantially all company assets remain in full force.

Next Steps

• Continue to increase direct-to-patient advertising for XTRAC in the United States to build market acceptance and motivate patients.
• Evaluate the effect of ASU 2023-09 (Income Tax Disclosures) on condensed consolidated financial statements and footnote disclosures.
• Evaluate the effect of ASU 2024-03 (Disaggregation of Income Statement Expenses) on condensed consolidated financial statements and footnote disclosures.
• Evaluate the effect of ASU 2025-05 (Credit Losses for Accounts Receivable) on condensed consolidated financial statements.
• Improve processes and controls, including senior management review, to remediate the material weakness in internal control over financial reporting.
• Write off the related product technology intangible asset of $0.7 million and derecognize the liability for contingent consideration of $1.2 million in the fourth quarter of 2025, following the Theravant Settlement.
• Commence royalty payments to Theravant equal to 5% of TheraClear X device sales, payable quarterly in arrears, starting on the later of January 1, 2027, or when annual domestic revenue from TheraClear X sales exceeds $2.5 million.
• Resume measurement of net revenue for financial covenant compliance with MidCap commencing with the first quarterly period ending after September 30, 2026.
• Begin making monthly principal payments on the Senior Term Facility starting July 1, 2026, for the remaining 24 months of the facility.

Key Dates

Recommendation

The company faces significant headwinds with declining revenues and ongoing net losses, alongside an identified material weakness in internal controls and unresolved sales tax liabilities. While management has taken proactive steps to address liquidity and going concern issues through debt covenant waivers and capital raises, and the Theravant settlement is a positive, the overall financial performance and external risks (geopolitical, tariffs, supply chain) suggest a cautious approach. The stock is not a strong buy given the challenges, but the recent actions to secure liquidity and address contingent liabilities prevent a strong sell. Investors should hold and monitor the effectiveness of remediation efforts and revenue stabilization.

Keywords

Dermatology, Medical Technology, XTRAC, TheraClear X, Excimer Laser, Psoriasis, Vitiligo, Acne, SEC Filing, 10-Q, Financial Results, Liquidity, Debt Covenant, Capital Raise, Internal Controls, Sales Tax, Supply Chain, Tariffs, Going Concern